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Abstract Despite the importance of cholesterol metabolism in 
the central nervous system, only relatively few studies have dealt 
with the cerebral uptake and transport of lipids into the brain 
compartment. These functions are mediated by the endothelium 
of brain microvessels, which forms the anatomical basis of the 
blood-brain barrier. By a reverse transcriptase PCR study of 
messenger RNA expression we could show, in bovine brain 
microvessels, the presence of transcripts of native low-density 
lipoprotein receptor and of both type I and II scavenger 
receptors. Brain microvessels therefore appear to play an active 
role in the uptake of native and modified low-density lipopro-
teins. 
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1. Introduction 
The low-density lipoprotein receptor (LDL-R) mediates the 
recognition and cellular uptake of plasma low-density lipopro-
tein (LDL). However, the LDL-R, which binds both apopro-
tein B-100 and apoprotein E, fails to recognize these apopro-
teins after their chemical modification, namely after their 
transformation into acetylated LDL (AcLDL) or oxidized 
LDL (OxLDL). These chemically modified LDLs are instead 
recognized by separate scavenger pathway(s), mediated by 
scavenger receptors (SCAV-Rs), which can also bind a broad 
but limited group of highly or abnormally negatively charged 
macromolecules and appear, from in vitro and in vivo studies, 
to be involved in the development of early atherosclerotic 
lesions (for review see: [1-4]). 
The SCAV-R bovine sequences have been cloned and char-
acterized as two distinct although closely related (type I and 
II) cDNAs [5,6]. The data on SCAV-Rs are, however, still 
incomplete in terms of tissue specificity and of developmental 
appearance. SCAV-Rs have been found, mainly by ligand 
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blotting and/or by 125I-labeled or fluorescent modified LDL 
uptake, to be present in macrophages [5-7], in various kinds 
of vascular endothelial cells (Ecs) [5,6,8-10], in fibroblasts and 
in smooth muscle cells (SMCs) [11,12]. Their presence has 
been reported in brain by some authors [13] but not by others 
[5]. 
Despite the importance of cholesterol metabolism in central 
nervous system (CNS), only a few studies have dealt with the 
cerebral uptake and transport of lipids into the brain. These 
functions are mediated by the endothelium of brain microves-
sels, whose morphological and functional characteristics differ 
from those of peripheral endothelia. The presence of tight 
junctions between the Ecs of brain microvessels and the low 
rate of pinocytosis and vesicular transport showed by these 
cells appear to be in fact the structural basis for its identifica-
tion with the blood-brain barrier (BBB), which prevents pas-
sive diffusion of compounds from the blood into the brain and 
contributes to the maintenance of the homeostasis of brain 
interstitial fluid [14,15]. In particular, despite some evidence 
for the presence of LDL-R on the Ecs of brain capillaries [16], 
little is known about the presence of SCAV-Rs, and the con-
clusions appear uncertain. 
Thus, while it has been reported that modified LDLs are 
not taken up in vivo by brain microvessels [8], very conflicting 
results have been obtained in vitro. In particular, although 
cultured cells from major cerebral arteries have been shown 
to be able to take up AcLDL [17], only a few authors 
[10,18,19] have demonstrated AcLDL uptake by microvascu-
lar Ecs isolated from bovine or rat brain, in contrast with 
others who failed to demonstrate such an activity on AcLDL 
and even on unmodified LDL [9]. Even those authors who 
have reported specific uptake of AcLDL by bovine cerebral 
Ecs in vitro have omitted to describe any sub-type distinction 
or data concerning the preferential transcription of these re-
ceptors. More recent studies [20] have shown, on the other 
hand, that the existence of a binding site for AcLDL, on 
cerebral Ecs in vitro, is not efficiently coupled to a degradative 
pathway. 
The present paper reports the expression of SCAV-Rs type 
I and II as well as of LDL-R in bovine brain microvessels, 
assessed by a reverse transcriptase PCR (RT-PCR) assay, in-
dicating the presence of different LDL uptake systems, in 
vivo, at the BBB level. 
2. Materials and methods 
2.1. Materials 
Random hexamers and oligo-d(T)ie were obtained from Perkin 
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Elmer Cetus Co. Super RT (AMV reverse transcriptase), Super Taq 
(Thermus thermophilus DNA polymerase), human placental ribonu-
clease inhibitor, buffer for reverse transcription, buffer for PCR and 
<£>XJHaellI marker were obtained from HT Biotechnology Ltd. Oli-
gonucleotides used as primers were synthesized by PRIMM. The re-
striction enzyme Hphl was obtained from New England Biolabs. All 
other chemicals were obtained from Sigma Chemical Co. 
2.2. Isolation and purity assay of brain microvessels 
All glassware used for transport or treatment of bovine brains was 
previously sterilized at 180°C for 8 h; whenever possible, disposable 
plasticware was used. All manipulations were performed with gloves 
and in ice. Fresh bovine brains were obtained from the local slaugh-
terhouse and immediately transported to the laboratory. Meninges 
were removed, and only the cortex was used. The capillaries were 
isolated using a previously described method [21,22], which produced 
preparations without significant contamination by perivascular cells. 
However, in order to reach the highest level of preparation purity and 
to exclude definitively any eventually remaining contamination by 
perivascular microglia, astrocytes or pericytes, the microvessel prep-
arations were treated, after the mechanical isolation procedure, with 
crude collagenase at 500 or 5000 U/mg of microvessel protein as 
described [22,23]. On small fractions of every preparation, alkaline 
phosphatase (EC 3.1.3.1) and y-glutamyltranspeptidase (EC 2.3.2.2) 
were routinely assayed, as a test for purity and reproducibility, using 
the methods of Torack and Barnett [24] and of Orlowski and Meister 
[25], respectively. The microvessel preparations were enriched in y-
glutamyltranspeptidase and in alkaline phosphatase with respect to 
gray matter (Table 1), according to previous data [21,26]. These en-
zymatic activities were decreased only partially following treatment 
with crude collagenase at 500 U/mg of microvessel protein; even 
when the isolated microvessels were treated with a 10-fold higher 
concentration of collagenase (5000 U/mg of microvessel protein) or 
subjected to longer incubation (data not shown), there were no further 
modifications of the enzymatic activities tested (Table 1 and [22]). This 
confirmed the close association existing between y-glutamyltranspep-
tidase and alkaline phosphatase with the brain Ecs, as reported pre-
viously [20,22,23], and demonstrated that the residual activity was 
unlikely to be due to contamination by other cells but is characteristic 
of Ecs of brain microvessels. Collagenase treatment at 500 U/mg and 
phase-contrast light microscopy observation were performed as rou-
tine steps in this work for sample purity achievement and assessment. 
The isolated brain microvessels to be used for total RNA extraction 
were then collected in sterile Petri dishes without buffer and stored at 
-80°C. 
2.3. DNA extraction, RNA extraction and cDNA synthesis 
DNA extraction, from bovine blood, was performed using a stand-
ard procedure [27], i.e. by lysis with 0.5% SDS and subsequent treat-
ment with proteinase K (100 ng/ml), followed by phenol extractions 
and ethanol precipitation. 1 ug of DNA was used for subsequent 
PCR. 
Total RNA extraction, from isolated brain microvessels, was per-
formed by the acid guanidinium/thiocyanate/phenol-chloroform pro-
cedure [28]. Quantitation and purity of preparations were assessed by 
reading the 260/280 nm absorbances, while RNA integrity was 
checked according to standard electrophoretic procedures [27]. Re-
verse transcription was performed with 1 ixg of total RNA, by using 
either 150 pmol of random hexamers or 50 pmol of oligo-d(T)i6 per 
sample, with 25 units per sample of Super RT at 42°C for 1 h, fol-
lowed by heat inactivation at 94°C for 5 min. Total reaction volume 
was of 20 |xl per sample, in the following assay buffer: 50 mM Tris-
HC1 pH 8.3, 50 mM KC1, 4 mM DTT, 10 mM MgCl2, human pla-
centa! ribonuclease inhibitor 20 units per sample, 200 |xM each of 
dGTP, dATP, dCTP and dTTP. In subsequent amplification reac-
tions, 7 ul of this volume were used for each PCR sample. 
2.4. PCR strategy and restriction analysis 
Starting from a cDNA mixture obtained by reverse transcription of 
brain microvessels mRNAs, the bovine LDL-R cDNA [29,30] was 
amplified by using BTLDLP19 (5'-TGCACTCCATCTCCAGCATC-
G-3') as forward primer and BTLDLM3 (5'-GAGGCAGCTTCT-
CATGTCCTTGG-3') as backward primer (Fig. 1A); an amplified 
fragment of 392 bp was obtained. For amplification of bovine 
SCAV-R cDNAs, we chose a couple of primers allowing amplification 
of the common part of SCAV-Rs type I [5] and type II [6], namely 
BTSCAVRP2 (5'-TGATGGAACGCATGAGCAACATGG-3') as 
forward primer and BTSCAVRM2 (5'-TGGTCCTGGGAATCCTC-
GAACTCC-3') as backward primer (Fig. IB). This couple of primers 
produced an amplified fragment of 626 bp, which could originate 
from the presence, in the total RNA preparation, of type I and/or 
type II mRNA of SCAV-R(s), as this couple of primers anneal at the 
ends of the common part of the cDNA sequence of these receptors. In 
order to distinguish between the two types of SCAV-Rs, we also 
performed amplifications using the same previously described forward 
primer BTSCAVRP2 coupled either with the backward primer 
BTSCAVRM3 (5'-CATCTTCGTCGTGCGAACAGGC-3'), which 
is specific for the cysteine-rich domain VI of type I (producing a 
1002 bp amplified fragment), or with the alternative backward primer 
BTSCAVRM2B (5'-TCGGTTTGGAGGAGCCACAAGG-3'), which 
is specific for the 3'-UTR of type II (producing a 864 bp amplified 
fragment) (Fig. IB). With the aim of assessing the specificity of am-
plified fragments both of LDL-R and of SCAV-R(s) and of studying 
the synonymous replacement of T by C at position 750 in type II, we 
used the restriction enzyme Hphl which is expected to produce differ-
ent restriction patterns in the cDNAs of the type I and II receptors 
(Fig. IB). In this regard, digestions were carried out on 5 ul of am-
plified PCR products, in a final volume of 50 ul, with 15 units of 
enzyme for 3 h at 37°C, using the buffer provided by the manufac-
turer. Restriction analysis was performed on the amplified fragments 
or, eventually, on re-amplified fragments purified from the gel and 
recovered with Amicon filters (Micropure 0.22+Microcon 50). As a 
positive control of retrotranscription and amplification we used 
yACTl (5'-TTCCAGCAGATGTGGATCAG-3') as forward primer 
and yACT2 (5'-AGCCGCATATAACTAGGGGT-3') as backward 
primer, which amplify the y-actin bovine mRNA producing an ampli-
fied fragment of 342 bp [31]. In all reactions we used 40 pmol of each 
primer and 1 unit of Super Taq DNA polymerase. PCR was per-
formed in a final volume of 50 ill in 10 mM Tris-HCl, pH 9.0, 50 
mM KC1, 1.5 mM MgCl2, 0.1% Triton X-100, 0.01% gelatin, 200 uM 
each of dGTP, dATP, dCTP and dTTP. After an initial denaturation 
step of 3 min at 94°C, we performed, on a Perkin Elmer Cetus Ther-
mal Cycler model 480, 30 cycles of 1 min at 94°C, 1 min at 60°C, 1.5 
min at 72°C, followed by 7 min at 72°C. 
2.5. Gel electrophoresis and size assignment 
Electrophoresis was performed in 1.8% (w/v) agarose gel in 1 XTBE 
(90 mM Tris-borate, 1 mM EDTA pH 8.0) with 0.5 itg/ml of ethidium 
bromide, loading on each lane 15 ni from the PCR reaction (out of 50 
|xl), supplemented with 5 ul of loading buffer (0.1% Orange G, 20%o 
(w/v) Ficoll, 10 mM EDTA pH 7.2). All gels were photographed with 
a Polaroid MP4 Land Camera using Polaroid 667 films. These films 
were scanned by with a Kodak Megaplus camera (model 1.4) and 
images acquired by a Bio Image (Millipore) computerized densi-
tometer. This procedure allowed both confirmation of the size of 
the amplified products of PCR, and characterization of the restriction 
analysis fragments, by comparison with standard marker OX/ífaelII. 
Original images were exported from Bio Image in TIFF format, im-
ported into Corel Draw software (Corel Corp.), labeled and printed 
with a Scitex Inkjet printer (model Iris 3047). 
3. Results 
By means of c D N A templates synthesized by reverse tran-
scription from total R N A of bovine brain microvessels, fol-
lowed by P C R performed with the primer pair BTLDLB19 
and BTLDLM3, we detected an amplified product of 392 bp 
corresponding to the LDL-R m R N A (Fig. 2, lane 5). R T -
P C R performed using the primers BTSCAVRP2 and 
BTSCAVRM2 showed a band of 626 bp which originated 
from the presence, in the total R N A preparat ion of bovine 
brain microvessels, of type I and/or type II m R N A of SCAV-
R(s) for modified LDLs, this pair of primers having been 
chosen because they anneal at the ends of the common part 
of the c D N A sequence of these receptors (Fig. 2, lane 8). A 
P C R product of 342 bp was obtained, as expected, using 
primers yACTl and yACT2 which correspond to the y-actin 
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Fig. 1. Structures of LDL-R and of SCAV-Rs and choice of suitable PCR primers. (A) Structure of the 3' half cDNA of bovine LDL-R, ac-
cording to Russell et al. [30]. (B) Structure of bovine SCAV-R cDNAs according to Kodama et al. [5] for type I and to Rohrer et al. [6] for 
type II. The solid lines represent the coding domain sequence (CDS). The dashed box indicates the common sequence between types I and II. 
Italic numbers denote the nucleotide positions. The location of primers used for PCR is shown by bold arrows, near the indication of the nu-
cleotide range of each primer. Filled circles indicate Hphl restriction enzyme sites relative to the regions amplified by BTLDLP19 and 
BTLDLM3, or BTSCAVRP2 and BTSCAVRM2 couples of primers; the open circle indicates the hypothetical additional restriction site for 
Hphl originating from the synonymous replacement of T by C in type II SCAV-R; larger bold numbers are dimensions of the amplified frag-
ments; smaller bold numbers denote dimensions of Hphl expected restriction fragments from amplified fragments. 
housekeeping gene (Fig. 2, lane 2). Collagenase treatment 
failed to affect the presence or abundance of the amplified 
fragment of the LDL-R (Fig. 2, lane 6), of the SCAV-R(s) 
(Fig. 2, lane 9), as well as of the y-actin gene (Fig. 2, lane 3). 
Similar patterns of amplified products, relative to the LDL-
R and to the SCAV-R(s), were obtained when RT was per-
formed by the use of either oligo(dT) or random hexamers 
(Fig. 3A, lanes 2,3,7,8). Using genomic DNA as template in 
PCR, the pair of primers BTLDLB19 and BTLDLM3 ampli-
fied a band of higher molecular weight (about 920 bp) than 
using the RNA template in RT-PCR (Fig. 3A, lane 6). This 
differential amplification (between cDNA and genomic DNA) 
enabled us to overcome the problem of genomic DNA inter-
ference in RT-PCR. In addition, PCR performed on genomic 
DNA, using the primers BTSCAVRP2 and BTSCAVRM2, 
failed to produce any amplified fragment (Fig. 3A, lane 11). 
With the aim of distinguishing between the two types of 
SCAV-Rs, we also performed selective amplifications using 
either the couple of primers BTSCAVRP2 and BTSCAVR-
M3, which produced an amplified fragment of 1002 bp specific 
for type I (Fig. 3B, lane 2), or the couple of primers 
BTSCAVRP2 and BTSCAVRM2B which produced an ampli-
fied fragment of 864 bp specific for type II (Fig. 3B, lane 4). 
We could conclude that both type I and II SCAV-R mRNA 
are present in bovine brain microvessels, since both amplified 
products could be obtained. 
Table 1 
Enzymatic activities in gray matter and in isolated brain microvessels after collagenase treatment 
Enzyme 
Alkaline phosphatase 
y-Glutamyltranspeptidase 
Gray matter 
18 ±7 (8) 
10 ±0.5 (7) 
Isolated microvessels collagenase treatment (U/mg of microvessel protein) 
None 500 5000 
182 ±39 (7) 142 ±8 (7) 138 ±10 (6) 
2148±410 (6) 1325±57 (7) 1350±40(7) 
The enzymatic activities were determined on the gray matter homogenate and on isolated microvessels treated, after the isolation procedure, with 
different collagenase concentrations. The enzyme levels were determined in triplicate for each preparation (the number of preparations is reported in 
parentheses). The mean values (± S.D.) of enzymatic activities are reported as mU/mg protein per min. 
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Fig. 2. RT-PCR amplified products from bovine brain microvessels 
before (—) and after (+) collagenase treatment (500 U/mg of micro-
vessel protein). (Lanes 2,3) Amplified products obtained using pri-
mers yACTl and yACT2, respectively, specific for bovine y-actin se-
quence; (lanes 5,6) amplified products obtained using primers 
BTLDLP19 and BTLDLM3, specific for bovine LDL-R sequence, 
respectively; (lanes 8,9) products obtained using primers 
BTSCAVRP2 and BTSCAVRM2, specific for the cDNA common 
portion of bovine SCAV-R types I and II, respectively; (lanes 
4,7,10) respective negative controls. The amplified products shown 
were obtained by PCR performed on cDNAs synthesized by oli-
go(dT) reverse transcription of total RNA. A <t>XIHaeIU marker is 
shown in lanes 1 and 11. 
The specificity of all RT-PCR products was evaluated by 
digestion with the Hphl restriction endonuclease which, in 
addition, recognizes a T->C transition at nucleotide 750 in 
the SCAV-R(s) cDNA. This substitution was initially consid-
ered type II specific [6], further evidence suggesting however 
the possibility of polymorphism of a single gene transcript 
[11,32]. Hphl digestion of the 626 bp amplified fragment, ob-
tained with the BTSCAVRP2 and BTSCAVRM2 primers, 
produced three fragments of 507, 81 and 38 bp, as expected 
from the presence of a T at nucleotide 750 (Fig. 4). In fact, the 
presence of a C at nucleotide 750 should produce an addi-
tional cut at location 401 (Fig. IB), the 507 bp band therefore 
being substituted by two bands of 401 and 106 bp. This result, 
together with the specific amplification of type II SCAV-R, 
obtained using primers BTSCAVRP2 and BTSCAVRM2B, 
confirmed that the synonymous replacement of T by C at 
position 750 is most probably an allelic variation rather 
than a sequence-specific feature of type II SCAV-R. This find-
ing agrees with previous evidence of a common gene coding 
for both type I and II human SCAV-Rs [33]. 
4. Discussion 
We have demonstrated the presence, in bovine brain micro-
vessels in vivo, of mRNAs for LDL-R as well as for type I 
and II SCAV-Rs. Our findings agree with previous evidence 
on the activity, in the brain microvasculature, of enzymes of 
lipoprotein metabolism [34], and demonstrate the presence, in 
CNS, of complete systems for lipid uptake and for de novo 
synthesis. 
Contrasting data had thus far been collected concerning the 
expression, in total brain as well as in cerebral microvessels, of 
receptorial systems involved in recognition of native or mod-
ified LDL. In particular, the presence of SCAV-Rs in total 
brain had been detected in bovine brain by some authors [13] 
but not by others, and Northern blot analysis performed with 
specific probes for SCAV-Rs type I [5] or type II [6] had failed 
to show any expression in bovine brain. The discrepancy be-
tween these negative results in total brain and our positive 
findings in cerebral microvessels can reasonably be ascribed 
to quantitative differences in the relative amounts of mRNA 
for SCAV-Rs, as well as to the higher sensitivity of RT-PCR 
with respect to Northern blot analysis. In addition to quanti-
tative effects, discrepancies in SCAV-Rs detection could also 
be due to the necessity of other concomitant patterns for the 
expression and/or for the functionality of these mRNAs. Sev-
eral differences between Ecs of brain capillaries vs. other 
blood vessels have indeed been attributed to the specific en-
vironment leading to the formation of a BBB [35]. Interac-
tions of brain Ecs with other cell types (e.g. astrocytes [36]) 
have been reported to affect the expression of both LDL-R 
and SCAV-Rs. Indeed, in confluent brain capillary Ecs, the 
LDL-R escapes the down-regulation mechanisms occurring in 
vascular Ecs of large vessels [16,36]. The expression of LDL-R 
and of SCAV-Rs is therefore likely to be modulated by cel-
lular interaction occurring in brain microvessels, with possible 
variations in this interaction according to the experimental 
design, particularly in vitro. 
Our data show that the uptake of both native and modified 
LDL by cerebral microvessels is likely to play a physiological 
role in the local clearance of native or modified lipoproteins 
from the circulation and in the lipid supply to the CNS com-
partment. The expression of SCAV-Rs, the LDL-R one (spe-
cifically in brain Ecs), and the subsequent internalization of 
native or modified LDLs are not down-regulated by high 
levels of intracellular cholesterol. Due to this escape from 
the common regulatory feedback, it may be speculated that 
the expression of these receptors can mediate an increase in 
the local concentration of LDL-carried cholesterol and in its 
availability to the other cells involved in pathological athero-
sclerotic processes. In cerebral microvascular Ecs, which re-
portedly behave differently from other Ecs under conditions 
of high cell-cell contacts, the relative fluxes of cholesterol 
through the native or modified LDL uptake pathways are 
likely to depend on the equilibrium between the different 
Fig. 3. Expression of LDL-R and of type I and II SCAV-Rs in 
brain microvessels. (A) Amplified products obtained by PCR per-
formed on cDNAs synthesized from total RNA by reverse tran-
scription with either oligo(dT) (lanes 2,7) or with random hexamers 
(lanes 3,8). As a check for DNA contamination, PCR was also per-
formed from total RNA without the reverse transcription step (lanes 
5,10). As a check for possible genomic DNA amplification, PCR 
was also performed on genomic DNA from bovine blood (lanes 
6,11). (Lanes 2-6) Results obtained using primers BTLDLP19 and 
BTLDLM3, specific for bovine LDL-R. (Lanes 7-11) Results ob-
tained using primers BTSCAVRP2 and BTSCAVRM2, specific for 
the cDNA common portion of bovine SCAV-R types I and II. 
(Lanes 4,9) Respective negative controls. A OXAffaelll marker is 
shown in lanes 1 and 12. (B) Amplified products obtained from to-
tal RNA by PCR performed on cDNAs synthesized by reverse tran-
scription with oligo(dT) (Lane 2 (and 3 as negative control)) Results 
obtained using primers BTSCAVRP2 and BTSCAVRM3, specific 
for the bovine SCAV-R type I. (Lane 4 (and 5 as negative control)) 
Results obtained using primers BTSCAVRP2 and BTSCAVRM2B, 
specific for the bovine SCAV-R type II. A <RX///aeIII marker is 
shown in lanes 1 and 6. 
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Fig. 4. HpKL restriction analysis. (A) Purified amplification products 
relative either to the 3'-half of bovine LDL-R, obtained using pri-
mers BTLDLP19 and BTLDLM3 (lane 2) or to the cDNA common 
portion of bovine SCAV-Rs, obtained using primers BTSCAVRP2 
and BTSCAVRM2 (lane 3,4); (lanes 5,7) respective negative con-
trols; (lanes 1,6) <&XJHaeIll marker. (B) Restriction analysis per-
formed with Hphl enzyme on the purified products shown in (A). 
The observed restriction patterns are reported for the amplified 
product relative to LDL-R (lanes 3,4), with the expected restriction 
pattern shown on the left and for the amplified product relative to 
the SCAV-Rs (lanes 6,7), with the expected restriction patterns for 
either type I or II shown on the right. Solid lines indicate the ex-
pected products of a complete digestion, dashed lines the expected 
products of partial digestion. The undigested amplification products 
relative to the LDL-R (lane 2) and to the SCAV-Rs (lane 5) are 
also reported as references. A OXTifaelll marker is shown in lanes 
1 and 8. 
down- and up-regulating stimuli acting on the expression of 
L D L - R and SCAV-Rs, which in vivo remain to be assessed. 
Although the uncontrolled cellular uptake of cholesterol is 
likely to increase the risk of atherosclerosis, indicating a cru-
cial role for LDL-R and SCAV-Rs in brain, the exact nature 
of involvement of these receptors remains to be established. A 
previous work [20], demonstrated by 1 2 5I-AcLDL binding, the 
uptake of modified L D L by cerebral Ecs in vitro, which was 
not efficiently coupled with intracellular degradation. The 
authors hypothesized that the low degradation rate of A c L D L 
could be the reflection of a possible transcellular route of the 
internalized ligands for SCAV-Rs. This hypothesis, although 
yet to be directly verified, would raise the possibility of lipo-
protein permeation through BBB, with pericytes assuming the 
task of binding native or modified L D L released from brain 
micro vessel Ecs. 
Our results demonstrate that a complete receptorial system 
for lipid uptake is present in BBB and strongly suggest that 
the scavenger pathway plays a central role also in this vascu-
lar district. This peculiarity can hypothetically be utilized for 
modified LDL-mediated drug-targeting [9] to this particular 
endothelium, e.g. by inserting inhibitors of cholesterol bio-
synthesis into modified LDLs or in suitably modified lipo-
somes [37]. 
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